Covered recipient · General Payments record
RICHARD K BOGAN
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$142,080.35
169 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $87,510.00 | 26 |
| Consulting Fee | $32,120.00 | 6 |
| Travel and Lodging | $18,160.48 | 63 |
| Food and Beverage | $4,289.87 | 74 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $140,617.79 | 152 |
| Merck Sharp & Dohme Corporation | $1,299.60 | 9 |
| Resmed Corp | $56.13 | 3 |
| Fisher & Paykel Healthcare Inc | $51.70 | 1 |
| ARBOR PHARMACEUTICALS, INC. | $26.89 | 2 |
| Novartis Pharmaceuticals Corporation | $17.18 | 1 |
| Currax Pharmaceuticals LLC | $11.06 | 1 |
Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RICHARD K BOGAN
NPI 1538347661 · CMS profile ID 160258
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
COLUMBIA, SC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1538347661?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RICHARD K BOGAN, NPI 1538347661, CMS profile ID 160258. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538347661?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). RICHARD K BOGAN, NPI 1538347661, CMS profile ID 160258. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538347661?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- RICHARD K BOGAN, NPI 1538347661, CMS profile ID 160258, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–169 of 169 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1538347661?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
169 matching records · $142,080.35 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–169 of 169.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $7.56 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183077 | CMS |
| JAZZ PHARMACEUTICALS INC. | $47.00 | 02/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183085 | CMS |
| JAZZ PHARMACEUTICALS INC. | $27.33 | 02/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183097 | CMS |
| JAZZ PHARMACEUTICALS INC. | $646.17 | 02/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183073 | CMS |
| JAZZ PHARMACEUTICALS INC. | $154.91 | 02/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183087 | CMS |
| JAZZ PHARMACEUTICALS INC. | $11.76 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684179409 | CMS |
| JAZZ PHARMACEUTICALS INC. | $413.69 | 02/12/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183045 | CMS |
| JAZZ PHARMACEUTICALS INC. | $3,500.00 | 02/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183075 | CMS |
| Novartis Pharmaceuticals Corporation | $17.18 | 02/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659116667 | CMS |
| JAZZ PHARMACEUTICALS INC. | $105.36 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183061 | CMS |
| JAZZ PHARMACEUTICALS INC. | $24.66 | 02/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183093 | CMS |
| JAZZ PHARMACEUTICALS INC. | $3,500.00 | 02/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183047 | CMS |
| JAZZ PHARMACEUTICALS INC. | $124.35 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183083 | CMS |
| JAZZ PHARMACEUTICALS INC. | $33.00 | 01/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684155297 | CMS |
| JAZZ PHARMACEUTICALS INC. | $8,840.00 | 01/30/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684155299 | CMS |
| JAZZ PHARMACEUTICALS INC. | $570.00 | 01/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183043 | CMS |
| JAZZ PHARMACEUTICALS INC. | $18.45 | 01/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684179407 | CMS |
| JAZZ PHARMACEUTICALS INC. | $125.00 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183491 | CMS |
| JAZZ PHARMACEUTICALS INC. | $125.00 | 01/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684183785 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $188,889.23 | 21 |
| PY2025 | Principal investigator | $893,595.41 | 524 |
| PY2024 | Recipient | $141,658.73 | 17 |
| PY2024 | Principal investigator | $546,297.96 | 292 |
| PY2023 | Recipient | $1,858.24 | 5 |
| PY2023 | Principal investigator | $780,969.56 | 153 |
| PY2022 | Principal investigator | $310,170.01 | 61 |
| PY2021 | Recipient | $2,452.50 | 1 |
| PY2021 | Principal investigator | $524,293.17 | 76 |
| PY2020 | Recipient | $3,733.38 | 36 |
| PY2020 | Principal investigator | $424,260.96 | 105 |
| PY2019 | Recipient | $836.61 | 2 |
| PY2019 | Principal investigator | $220,311.79 | 94 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
545 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Avadel CNS Pharmaceuticals, LLC | $156,452.60 | 12/31/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS LLC | A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) | No dispute reported | 06/30/2026 | 1208554185 |
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 12/23/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208612891 |
| Principal investigator 1 | Alkermes, Inc. | $706.00 | 12/23/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614136 |
| Principal investigator 1 | Alkermes, Inc. | $6,100.00 | 12/23/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624931 |
| Principal investigator 1 | Alkermes, Inc. | $2,152.00 | 12/23/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625165 |
| Principal investigator 1 | Alkermes, Inc. | $1,317.00 | 12/23/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626448 |
| Principal investigator 1 | PFIZER INC. | $1,339.39 | 12/19/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS | AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD | No dispute reported | 06/30/2026 | 1228736313 |
| Principal investigator 1 | Alkermes, Inc. | $2,083.00 | 12/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624300 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 12/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624698 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,087.70 | 12/05/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262732 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $650.00 | 12/05/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262734 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,300.00 | 12/05/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262736 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,300.00 | 12/05/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262738 |
| Principal investigator 1 | Alkermes, Inc. | $136.80 | 12/04/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616891 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $12.48 | 11/24/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737795 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3.01 | 11/24/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737797 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.65 | 11/24/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737799 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.04 | 11/24/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737801 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.65 | 11/24/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737803 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.24 | 11/24/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737805 |
| Principal investigator 1 | Alkermes, Inc. | $1,891.00 | 11/19/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613689 |
| Principal investigator 1 | Alkermes, Inc. | $2,512.00 | 11/19/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615395 |
| Principal investigator 1 | Alkermes, Inc. | $6,588.00 | 11/19/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619421 |
| Principal investigator 1 | Alkermes, Inc. | $5,171.00 | 11/19/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623164 |
| Principal investigator 1 | Breas Medical, Inc. | $131.79 | 11/19/2025 | Non-covered Recipient Entity Bogan Sleep Consultants | Vivo NOVA | No dispute reported | 06/30/2026 | 1249851740 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,234.70 | 11/19/2025 | Covered Recipient Physician | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223262730 |
| Principal investigator 1 | Alkermes, Inc. | $2,083.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613245 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613247 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614140 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617331 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620115 |
| Principal investigator 1 | Alkermes, Inc. | $1,133.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621210 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622908 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622910 |
| Principal investigator 1 | Alkermes, Inc. | $2,083.00 | 11/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626654 |
| Principal investigator 1 | Alkermes, Inc. | $259.54 | 11/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613241 |
| Principal investigator 1 | Alkermes, Inc. | $54.72 | 11/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616049 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $34,825.05 | 11/03/2025 | Covered Recipient Physician | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223262728 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245553791 |
| Principal investigator 1 | LivaNova USA, Inc. | $691.25 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245553795 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554004 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554008 |
| Principal investigator 1 | LivaNova USA, Inc. | $691.25 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554012 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554017 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554021 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554025 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554029 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554033 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554038 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554042 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554046 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,028.75 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | (OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation | No dispute reported | 06/30/2026 | 1245554147 |
| Principal investigator 1 | LivaNova USA, Inc. | $725.00 | 10/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | (OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation | No dispute reported | 06/30/2026 | 1245554152 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613031 |
| Principal investigator 1 | Alkermes, Inc. | $3,352.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613243 |
| Principal investigator 1 | Alkermes, Inc. | $4,272.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613667 |
| Principal investigator 1 | Alkermes, Inc. | $2,005.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615213 |
| Principal investigator 1 | Alkermes, Inc. | $706.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617113 |
| Principal investigator 1 | Alkermes, Inc. | $5,041.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617329 |
| Principal investigator 1 | Alkermes, Inc. | $2,135.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618469 |
| Principal investigator 1 | Alkermes, Inc. | $706.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620568 |
| Principal investigator 1 | Alkermes, Inc. | $5,171.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622243 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626030 |
| Principal investigator 1 | Alkermes, Inc. | $752.00 | 10/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626900 |
| Principal investigator 1 | Alkermes, Inc. | $1,500.00 | 10/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208614346 |
| Principal investigator 1 | Alkermes, Inc. | $1,879.00 | 10/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615197 |
| Principal investigator 1 | Alkermes, Inc. | $6,667.00 | 10/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615383 |
| Principal investigator 1 | Alkermes, Inc. | $615.00 | 10/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620325 |
| Principal investigator 1 | Alkermes, Inc. | $1,300.00 | 10/10/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620570 |
| Principal investigator 1 | Breas Medical, Inc. | $65.67 | 10/09/2025 | Non-covered Recipient Entity Bogan Sleep Consultants | Vivo NOVA | No dispute reported | 06/30/2026 | 1238854144 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 10/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616051 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 10/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617739 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 10/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617741 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 10/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618205 |
| Principal investigator 1 | Alkermes, Inc. | $1,133.00 | 10/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621847 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 10/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624732 |
| Principal investigator 1 | Alkermes, Inc. | $1,133.00 | 10/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624935 |
| Principal investigator 1 | Alkermes, Inc. | $71.60 | 10/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616515 |
| Principal investigator 1 | Alkermes, Inc. | $225.25 | 10/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618203 |
| Principal investigator 1 | Alkermes, Inc. | $259.54 | 10/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620996 |
| Principal investigator 1 | Alkermes, Inc. | $94.00 | 10/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624730 |
| Principal investigator 1 | Alkermes, Inc. | $54.72 | 10/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626450 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208612955 |
| Principal investigator 1 | Alkermes, Inc. | $6,588.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614467 |
| Principal investigator 1 | Alkermes, Inc. | $3,352.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616173 |
| Principal investigator 1 | Alkermes, Inc. | $2,135.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617443 |
| Principal investigator 1 | Alkermes, Inc. | $706.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618609 |
| Principal investigator 1 | Alkermes, Inc. | $2,094.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619295 |
| Principal investigator 1 | Alkermes, Inc. | $5,041.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620696 |
| Principal investigator 1 | Alkermes, Inc. | $752.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621124 |
| Principal investigator 1 | Alkermes, Inc. | $6,588.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621518 |
| Principal investigator 1 | Alkermes, Inc. | $4,272.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622187 |
| Principal investigator 1 | Alkermes, Inc. | $5,041.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622189 |
| Principal investigator 1 | Alkermes, Inc. | $5,171.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623540 |
| Principal investigator 1 | Alkermes, Inc. | $6,100.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623740 |
| Principal investigator 1 | Alkermes, Inc. | $2,005.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623742 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624424 |
| Principal investigator 1 | Alkermes, Inc. | $2,005.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625079 |
| Principal investigator 1 | Alkermes, Inc. | $752.00 | 09/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625303 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,866.50 | 09/12/2025 | Covered Recipient Physician | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223262726 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $22,847.50 | 09/10/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737767 |
| Principal investigator 1 | Alkermes, Inc. | $739.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614046 |
| Principal investigator 1 | Alkermes, Inc. | $752.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614048 |
| Principal investigator 1 | Alkermes, Inc. | $712.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614475 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618121 |
| Principal investigator 1 | Alkermes, Inc. | $752.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619063 |
| Principal investigator 1 | Alkermes, Inc. | $752.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619801 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620912 |
| Principal investigator 1 | Alkermes, Inc. | $1,833.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622415 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622419 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624190 |
| Principal investigator 1 | Alkermes, Inc. | $2,083.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625313 |
| Principal investigator 1 | Alkermes, Inc. | $2,133.00 | 09/08/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625786 |
| Principal investigator 1 | Alkermes, Inc. | $172.25 | 09/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613175 |
| Principal investigator 1 | Alkermes, Inc. | $56.40 | 09/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613385 |
| Principal investigator 1 | Alkermes, Inc. | $75.20 | 09/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614927 |
| Principal investigator 1 | Alkermes, Inc. | $51.75 | 09/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618833 |
| Principal investigator 1 | Alkermes, Inc. | $71.60 | 09/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619797 |
| Principal investigator 1 | Alkermes, Inc. | $150.40 | 09/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621122 |
| Principal investigator 1 | Alkermes, Inc. | $185.50 | 09/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208622185 |
| Principal investigator 1 | Alkermes, Inc. | $71.60 | 09/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626800 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $81.90 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737759 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $652.47 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737763 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $81.90 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737765 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $128.70 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737769 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737771 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $83.20 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737775 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737779 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $81.90 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737781 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $128.70 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737783 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737785 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $83.20 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737787 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $83.20 | 09/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737789 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $90.00 | 09/01/2025 | Non-covered Recipient Entity Advarra, Inc. | Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder | No dispute reported | 06/30/2026 | 1243525159 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 08/27/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618301 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 08/27/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626108 |
| Principal investigator 1 | Alkermes, Inc. | $6,100.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613387 |
| Principal investigator 1 | Alkermes, Inc. | $2,135.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208614709 |
| Principal investigator 1 | Alkermes, Inc. | $3,352.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616413 |
| Principal investigator 1 | Alkermes, Inc. | $6,100.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617031 |
| Principal investigator 1 | Alkermes, Inc. | $3,352.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620908 |
| Principal investigator 1 | Alkermes, Inc. | $2,094.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621522 |
| Principal investigator 1 | Alkermes, Inc. | $2,094.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621524 |
| Principal investigator 1 | Alkermes, Inc. | $4,272.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623318 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625968 |
| Principal investigator 1 | Alkermes, Inc. | $2,135.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626172 |
| Principal investigator 1 | Alkermes, Inc. | $4,272.00 | 08/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208626584 |
| Principal investigator 1 | Alkermes, Inc. | $70.00 | 08/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623014 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 08/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617859 |
| Principal investigator 1 | Alkermes, Inc. | $2,054.00 | 08/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625083 |
| Principal investigator 1 | Alkermes, Inc. | $136.80 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613383 |
| Principal investigator 1 | Alkermes, Inc. | $6,724.00 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618357 |
| Principal investigator 1 | Alkermes, Inc. | $6,724.00 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618615 |
| Principal investigator 1 | Alkermes, Inc. | $4,273.00 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619799 |
| Principal investigator 1 | Alkermes, Inc. | $1,133.00 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622193 |
| Principal investigator 1 | Alkermes, Inc. | $38.82 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623316 |
| Principal investigator 1 | Alkermes, Inc. | $4,273.00 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623962 |
| Principal investigator 1 | Alkermes, Inc. | $54.72 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625301 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625309 |
| Principal investigator 1 | Alkermes, Inc. | $4,273.00 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625553 |
| Principal investigator 1 | Alkermes, Inc. | $6,724.00 | 08/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626174 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $50,533.60 | 08/06/2025 | Covered Recipient Physician | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223262722 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $15,574.00 | 08/06/2025 | Covered Recipient Physician | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223262724 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,797.38 | 07/25/2025 | Covered Recipient Physician | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223262720 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,479.00 | 07/23/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737777 |
| Principal investigator 1 | LivaNova USA, Inc. | $135.00 | 07/18/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245553788 |
| Principal investigator 1 | LivaNova USA, Inc. | $135.00 | 07/18/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | (OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation | No dispute reported | 06/30/2026 | 1245554176 |
| Principal investigator 1 | Alkermes, Inc. | $688.00 | 07/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614264 |
| Principal investigator 1 | Alkermes, Inc. | $6,136.00 | 07/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614479 |
| Principal investigator 1 | Alkermes, Inc. | $2,125.00 | 07/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614717 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 07/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614719 |
| Principal investigator 1 | Alkermes, Inc. | $712.00 | 07/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617445 |
| Principal investigator 1 | Alkermes, Inc. | $712.00 | 07/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621732 |
| Principal investigator 1 | Alkermes, Inc. | $4,832.00 | 07/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624428 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 07/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626804 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $4,970.15 | 07/16/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262718 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2,352.74 | 07/11/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737793 |
| Principal investigator 1 | Alkermes, Inc. | $2,028.00 | 07/09/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620484 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,895.00 | 07/09/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737761 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 07/09/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737773 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $993.00 | 07/09/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737791 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $5,500.00 | 07/09/2025 | Covered Recipient Physician | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223262712 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 07/09/2025 | Covered Recipient Physician | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223262714 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $1,200.00 | 07/09/2025 | Covered Recipient Physician | A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS | No dispute reported | 06/30/2026 | 1223262716 |
| Principal investigator 1 | Alkermes, Inc. | $1.74 | 07/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614925 |
| Principal investigator 1 | Alkermes, Inc. | $93.50 | 07/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616797 |
| Principal investigator 1 | Alkermes, Inc. | $25.70 | 07/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618353 |
| Principal investigator 1 | Alkermes, Inc. | $74.24 | 07/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619549 |
| Principal investigator 1 | Alkermes, Inc. | $8.04 | 07/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621965 |
| Principal investigator 1 | Alkermes, Inc. | $3.50 | 07/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622599 |
| Principal investigator 1 | Alkermes, Inc. | $21.40 | 07/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623538 |
| Principal investigator 1 | Alkermes, Inc. | $109.20 | 07/02/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623958 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 06/27/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208617005 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 06/27/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619257 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $4,033.00 | 06/25/2025 | Covered Recipient Physician | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223262710 |
| Principal investigator 1 | Alkermes, Inc. | $3.48 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208612905 |
| Principal investigator 1 | Alkermes, Inc. | $72.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208612969 |
| Principal investigator 1 | Alkermes, Inc. | $77.10 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613411 |
| Principal investigator 1 | Alkermes, Inc. | $51.40 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614064 |
| Principal investigator 1 | Alkermes, Inc. | $109.20 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614292 |
| Principal investigator 1 | Alkermes, Inc. | $50.15 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614302 |
| Principal investigator 1 | Alkermes, Inc. | $11.76 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614499 |
| Principal investigator 1 | Alkermes, Inc. | $10.50 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614959 |
| Principal investigator 1 | Alkermes, Inc. | $72.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615159 |
| Principal investigator 1 | Alkermes, Inc. | $100.30 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615173 |
| Principal investigator 1 | Alkermes, Inc. | $3.48 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615287 |
| Principal investigator 1 | Alkermes, Inc. | $12.06 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615461 |
| Principal investigator 1 | Alkermes, Inc. | $2.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615989 |
| Principal investigator 1 | Alkermes, Inc. | $74.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616109 |
| Principal investigator 1 | Alkermes, Inc. | $93.50 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616363 |
| Principal investigator 1 | Alkermes, Inc. | $3.50 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616443 |
| Principal investigator 1 | Alkermes, Inc. | $5.60 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616813 |
| Principal investigator 1 | Alkermes, Inc. | $58.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616851 |
| Principal investigator 1 | Alkermes, Inc. | $24.12 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617013 |
| Principal investigator 1 | Alkermes, Inc. | $162.05 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617201 |
| Principal investigator 1 | Alkermes, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617281 |
| Principal investigator 1 | Alkermes, Inc. | $93.50 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618055 |
| Principal investigator 1 | Alkermes, Inc. | $19.60 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618083 |
| Principal investigator 1 | Alkermes, Inc. | $25.00 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618153 |
| Principal investigator 1 | Alkermes, Inc. | $31.36 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618317 |
| Principal investigator 1 | Alkermes, Inc. | $17.12 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619585 |
| Principal investigator 1 | Alkermes, Inc. | $145.60 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619821 |
| Principal investigator 1 | Alkermes, Inc. | $59.92 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619839 |
| Principal investigator 1 | Alkermes, Inc. | $72.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620508 |
| Principal investigator 1 | Alkermes, Inc. | $93.50 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620856 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620934 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621478 |
| Principal investigator 1 | Alkermes, Inc. | $2.10 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621766 |
| Principal investigator 1 | Alkermes, Inc. | $34.35 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621782 |
| Principal investigator 1 | Alkermes, Inc. | $51.55 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621999 |
| Principal investigator 1 | Alkermes, Inc. | $16.00 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622211 |
| Principal investigator 1 | Alkermes, Inc. | $254.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622213 |
| Principal investigator 1 | Alkermes, Inc. | $205.60 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622837 |
| Principal investigator 1 | Alkermes, Inc. | $231.30 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622839 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622848 |
| Principal investigator 1 | Alkermes, Inc. | $2.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622850 |
| Principal investigator 1 | Alkermes, Inc. | $12.06 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623284 |
| Principal investigator 1 | Alkermes, Inc. | $148.48 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623348 |
| Principal investigator 1 | Alkermes, Inc. | $8.56 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623366 |
| Principal investigator 1 | Alkermes, Inc. | $148.48 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623566 |
| Principal investigator 1 | Alkermes, Inc. | $2.14 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624020 |
| Principal investigator 1 | Alkermes, Inc. | $42.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624242 |
| Principal investigator 1 | Alkermes, Inc. | $15.68 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624592 |
| Principal investigator 1 | Alkermes, Inc. | $27.44 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624840 |
| Principal investigator 1 | Alkermes, Inc. | $24.12 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625259 |
| Principal investigator 1 | Alkermes, Inc. | $51.40 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625331 |
| Principal investigator 1 | Alkermes, Inc. | $4.90 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625561 |
| Principal investigator 1 | Alkermes, Inc. | $16.08 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625728 |
| Principal investigator 1 | Alkermes, Inc. | $51.40 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625802 |
| Principal investigator 1 | Alkermes, Inc. | $1.05 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626000 |
| Principal investigator 1 | Alkermes, Inc. | $54.60 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626376 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626522 |
| Principal investigator 1 | Alkermes, Inc. | $359.80 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626840 |
| Principal investigator 1 | Alkermes, Inc. | $32.70 | 06/18/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626848 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,027.00 | 06/13/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737749 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,500.00 | 06/13/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737755 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,895.00 | 06/13/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737757 |
| Principal investigator 1 | Alkermes, Inc. | $1,880.00 | 06/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616545 |
| Principal investigator 1 | Alkermes, Inc. | $1,980.00 | 06/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618257 |
| Principal investigator 1 | Alkermes, Inc. | $2,125.00 | 06/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622723 |
| Principal investigator 1 | Alkermes, Inc. | $4,691.00 | 06/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622725 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 06/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622727 |
| Principal investigator 1 | Alkermes, Inc. | $688.00 | 06/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622964 |
| Principal investigator 1 | Alkermes, Inc. | $1,880.00 | 06/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625183 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 06/11/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626070 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $0.96 | 06/11/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737747 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.72 | 06/11/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737751 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $0.48 | 06/11/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737753 |
| Principal investigator 1 | Alkermes, Inc. | $30.61 | 06/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623638 |
| Principal investigator 1 | Alkermes, Inc. | $341.02 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208613990 |
| Principal investigator 1 | Alkermes, Inc. | $135.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615671 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615913 |
| Principal investigator 1 | Alkermes, Inc. | $135.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616567 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208618999 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619733 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208619735 |
| Principal investigator 1 | Alkermes, Inc. | $136.80 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620065 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208620419 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621272 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621274 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623260 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208623910 |
| Principal investigator 1 | Alkermes, Inc. | $341.02 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624386 |
| Principal investigator 1 | Alkermes, Inc. | $35.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208624568 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625017 |
| Principal investigator 1 | Alkermes, Inc. | $20.00 | 06/06/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208625704 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 06/04/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208619645 |
| Principal investigator 1 | Alkermes, Inc. | $2,157.00 | 06/04/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621188 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 06/04/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622894 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 06/04/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623406 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 06/04/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624046 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $3,893.50 | 06/04/2025 | Covered Recipient Physician | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223262708 |
| Principal investigator 1 | Alkermes, Inc. | $712.00 | 05/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614330 |
| Principal investigator 1 | Alkermes, Inc. | $712.00 | 05/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619379 |
| Principal investigator 1 | Alkermes, Inc. | $712.00 | 05/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619869 |
| Principal investigator 1 | Alkermes, Inc. | $712.00 | 05/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622473 |
| Principal investigator 1 | Alkermes, Inc. | $712.00 | 05/16/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623802 |
| Principal investigator 1 | LivaNova USA, Inc. | $16.88 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245553784 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554000 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554050 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554054 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554058 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554063 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554066 |
| Principal investigator 1 | LivaNova USA, Inc. | $16.88 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554070 |
| Principal investigator 1 | LivaNova USA, Inc. | $16.88 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554074 |
| Principal investigator 1 | LivaNova USA, Inc. | $16.88 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554077 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554080 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554085 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554088 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554092 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554096 |
| Principal investigator 1 | LivaNova USA, Inc. | $337.50 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554100 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554103 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554107 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554113 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554120 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554124 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554127 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554131 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554134 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554138 |
| Principal investigator 1 | LivaNova USA, Inc. | $10,662.52 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | (OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation | No dispute reported | 06/30/2026 | 1245554143 |
| Principal investigator 1 | LivaNova USA, Inc. | $10,662.52 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | (OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation | No dispute reported | 06/30/2026 | 1245554184 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554272 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554277 |
| Principal investigator 1 | LivaNova USA, Inc. | $337.50 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554281 |
| Principal investigator 1 | LivaNova USA, Inc. | $270.00 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554284 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 05/16/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554288 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $10,572.60 | 05/14/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262706 |
| Principal investigator 1 | Alkermes, Inc. | $2,073.00 | 05/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614382 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 05/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615883 |
| Principal investigator 1 | Alkermes, Inc. | $3,988.00 | 05/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618015 |
| Principal investigator 1 | Alkermes, Inc. | $688.00 | 05/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624102 |
| Principal investigator 1 | Alkermes, Inc. | $5,989.00 | 05/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624346 |
| Principal investigator 1 | Alkermes, Inc. | $3,281.00 | 05/07/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626302 |
| Principal investigator 1 | Alkermes, Inc. | $1,133.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613237 |
| Principal investigator 1 | Alkermes, Inc. | $2,083.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613447 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613663 |
| Principal investigator 1 | Alkermes, Inc. | $2,083.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208613876 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614783 |
| Principal investigator 1 | Alkermes, Inc. | $1,384.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615561 |
| Principal investigator 1 | Alkermes, Inc. | $2,157.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615815 |
| Principal investigator 1 | Alkermes, Inc. | $1,384.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616027 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616257 |
| Principal investigator 1 | Alkermes, Inc. | $2,157.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616259 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617111 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617325 |
| Principal investigator 1 | Alkermes, Inc. | $1,133.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620321 |
| Principal investigator 1 | Alkermes, Inc. | $2,630.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620560 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621596 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208622898 |
| Principal investigator 1 | Alkermes, Inc. | $280.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624050 |
| Principal investigator 1 | Alkermes, Inc. | $2,157.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208624290 |
| Principal investigator 1 | Alkermes, Inc. | $2,083.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626026 |
| Principal investigator 1 | Alkermes, Inc. | $2,083.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626424 |
| Principal investigator 1 | Alkermes, Inc. | $2,630.00 | 05/05/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626650 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $1,345.00 | 04/28/2025 | Non-covered Recipient Entity Advarra, Inc. | Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder | No dispute reported | 06/30/2026 | 1243525148 |
| Principal investigator 1 | Alkermes, Inc. | $118.56 | 04/25/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614649 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $19,385.00 | 04/25/2025 | Non-covered Recipient Entity BoganSleep Consultants, LLC | Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder | No dispute reported | 06/30/2026 | 1243531854 |
| Principal investigator 1 | Alkermes, Inc. | $1,045.00 | 04/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208616969 |
| Principal investigator 1 | Alkermes, Inc. | $1,045.00 | 04/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208621458 |
| Principal investigator 1 | Alkermes, Inc. | $1,880.00 | 04/21/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208618739 |
| Principal investigator 1 | Alkermes, Inc. | $3,988.00 | 04/21/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621640 |
| Principal investigator 1 | Alkermes, Inc. | $1,880.00 | 04/21/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208622527 |
| Principal investigator 1 | Alkermes, Inc. | $2,073.00 | 04/21/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625672 |
| Principal investigator 1 | Alkermes, Inc. | $2,125.00 | 04/21/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626074 |
| Principal investigator 1 | Alkermes, Inc. | $102.80 | 04/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623782 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $11,484.75 | 04/02/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262704 |
| Principal investigator 1 | Alkermes, Inc. | $1,196.53 | 03/20/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) | No dispute reported | 06/30/2026 | 1208615107 |
| Principal investigator 1 | IDORSIA PHARMACEUTICALS US INC | $90.00 | 03/17/2025 | Non-covered Recipient Entity Advarra, Inc. | Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administration of Daridorexant in Pediatric Subjects Aged 10 to < 18 Years With Insomnia Disorder | No dispute reported | 06/30/2026 | 1243525153 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $16,831.50 | 03/05/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262702 |
| Principal investigator 1 | Alkermes, Inc. | $82.08 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615425 |
| Principal investigator 1 | Alkermes, Inc. | $119.36 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615525 |
| Principal investigator 1 | Alkermes, Inc. | $119.36 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615881 |
| Principal investigator 1 | Alkermes, Inc. | $113.34 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616081 |
| Principal investigator 1 | Alkermes, Inc. | $56.85 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616325 |
| Principal investigator 1 | Alkermes, Inc. | $113.34 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617159 |
| Principal investigator 1 | Alkermes, Inc. | $259.54 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617171 |
| Principal investigator 1 | Alkermes, Inc. | $52.48 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617399 |
| Principal investigator 1 | Alkermes, Inc. | $77.64 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617773 |
| Principal investigator 1 | Alkermes, Inc. | $52.48 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617905 |
| Principal investigator 1 | Alkermes, Inc. | $228.53 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618405 |
| Principal investigator 1 | Alkermes, Inc. | $77.64 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618753 |
| Principal investigator 1 | Alkermes, Inc. | $75.80 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620085 |
| Principal investigator 1 | Alkermes, Inc. | $259.54 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621164 |
| Principal investigator 1 | Alkermes, Inc. | $82.08 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621887 |
| Principal investigator 1 | Alkermes, Inc. | $56.85 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208625343 |
| Principal investigator 1 | Alkermes, Inc. | $228.53 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626078 |
| Principal investigator 1 | Alkermes, Inc. | $136.80 | 03/03/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626700 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 02/28/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737653 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $35.00 | 02/28/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737715 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 02/28/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737717 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $42.00 | 02/28/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737729 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9,986.00 | 02/21/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737655 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $8,327.00 | 02/21/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737741 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $6,500.00 | 02/21/2025 | Covered Recipient Physician | A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH) | No dispute reported | 06/30/2026 | 1223262700 |
| Principal investigator 1 | LivaNova USA, Inc. | $17,990.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | (OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation | No dispute reported | 06/30/2026 | 1245554179 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554235 |
| Principal investigator 1 | LivaNova USA, Inc. | $758.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554238 |
| Principal investigator 1 | LivaNova USA, Inc. | $337.50 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554243 |
| Principal investigator 1 | LivaNova USA, Inc. | $270.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554247 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554252 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554257 |
| Principal investigator 1 | LivaNova USA, Inc. | $540.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554260 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,885.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554265 |
| Principal investigator 1 | LivaNova USA, Inc. | $83.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554268 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554375 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554380 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554384 |
| Principal investigator 1 | LivaNova USA, Inc. | $270.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554387 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554391 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554395 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554399 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554404 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554408 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554413 |
| Principal investigator 1 | LivaNova USA, Inc. | $758.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554417 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554421 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554424 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554428 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554432 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554436 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554467 |
| Principal investigator 1 | LivaNova USA, Inc. | $33.75 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554472 |
| Principal investigator 1 | LivaNova USA, Inc. | $1,835.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554475 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554479 |
| Principal investigator 1 | LivaNova USA, Inc. | $590.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | OSPREY | No dispute reported | 06/30/2026 | 1245554482 |
| Principal investigator 1 | LivaNova USA, Inc. | $17,990.00 | 02/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | (OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation | No dispute reported | 06/30/2026 | 1245554530 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208614999 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615361 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208615787 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208616007 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208617695 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618439 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208618683 |
| Principal investigator 1 | Alkermes, Inc. | $650.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208620752 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621568 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208621584 |
| Principal investigator 1 | Alkermes, Inc. | $650.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208623116 |
| Principal investigator 1 | Alkermes, Inc. | $290.00 | 02/13/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208626402 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613013 |
| Principal investigator 1 | Alkermes, Inc. | $2,054.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613015 |
| Principal investigator 1 | Alkermes, Inc. | $52.80 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613311 |
| Principal investigator 1 | Alkermes, Inc. | $412.40 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208613970 |
| Principal investigator 1 | Alkermes, Inc. | $89.95 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615621 |
| Principal investigator 1 | Alkermes, Inc. | $15.39 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208615885 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616017 |
| Principal investigator 1 | Alkermes, Inc. | $162.05 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616313 |
| Principal investigator 1 | Alkermes, Inc. | $47.75 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208616955 |
| Principal investigator 1 | Alkermes, Inc. | $6.40 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208617383 |
| Principal investigator 1 | Alkermes, Inc. | $1,880.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617503 |
| Principal investigator 1 | Alkermes, Inc. | $2,054.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617689 |
| Principal investigator 1 | Alkermes, Inc. | $9.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208618955 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619141 |
| Principal investigator 1 | Alkermes, Inc. | $2,054.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619633 |
| Principal investigator 1 | Alkermes, Inc. | $739.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619635 |
| Principal investigator 1 | Alkermes, Inc. | $1.71 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208620167 |
| Principal investigator 1 | Alkermes, Inc. | $77.10 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208621436 |
| Principal investigator 1 | Alkermes, Inc. | $100.30 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208623668 |
| Principal investigator 1 | Alkermes, Inc. | $739.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625367 |
| Principal investigator 1 | Alkermes, Inc. | $739.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625369 |
| Principal investigator 1 | Alkermes, Inc. | $50.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208625676 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 02/12/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625850 |
| Recipient | Takeda Pharmaceuticals U.S.A., Inc. | $8,734.80 | 02/05/2025 | Covered Recipient Physician | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223262698 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $412.10 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737645 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $235.30 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737647 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737649 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737651 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737657 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.30 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737661 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $913.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737663 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $83.20 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737665 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $159.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737667 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,177.80 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737669 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737671 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $83.20 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737673 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737675 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $215.28 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737677 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $235.30 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737679 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,258.40 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737681 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,177.80 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737683 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,177.80 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737685 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,644.60 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737687 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $83.20 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737689 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $83.20 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737691 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $128.70 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737693 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,800.50 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737695 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,177.80 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737697 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $119.47 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737703 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,258.40 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737705 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $8,299.20 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737707 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,025.10 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737709 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737711 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,654.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737713 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,212.90 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737719 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $314.60 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737721 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $97.50 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737723 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $527.15 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737725 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3,438.50 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737727 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $128.70 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737731 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $128.70 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737733 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $24.70 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737735 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $31.20 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737739 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,800.50 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737743 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,800.50 | 02/03/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | No dispute reported | 06/30/2026 | 1233737745 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 01/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737659 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $35.00 | 01/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737699 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.00 | 01/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737701 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $42.00 | 01/31/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | No dispute reported | 06/30/2026 | 1233737737 |
| Principal investigator 1 | Alkermes, Inc. | $10,038.00 | 01/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620097 |
| Principal investigator 1 | Alkermes, Inc. | $7,341.00 | 01/22/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626876 |
| Principal investigator 1 | Alkermes, Inc. | $4,832.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613023 |
| Principal investigator 1 | Alkermes, Inc. | $688.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613225 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613665 |
| Principal investigator 1 | Alkermes, Inc. | $739.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208613880 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614539 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208614771 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208615547 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616261 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208616879 |
| Principal investigator 1 | Alkermes, Inc. | $688.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208617945 |
| Principal investigator 1 | Alkermes, Inc. | $6,136.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208619857 |
| Principal investigator 1 | Alkermes, Inc. | $4,832.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620307 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208620323 |
| Principal investigator 1 | Alkermes, Inc. | $688.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621390 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621813 |
| Principal investigator 1 | Alkermes, Inc. | $2,054.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208621829 |
| Principal investigator 1 | Alkermes, Inc. | $6,136.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623398 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623400 |
| Principal investigator 1 | Alkermes, Inc. | $2,054.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208623602 |
| Principal investigator 1 | Alkermes, Inc. | $4,832.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624274 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208624276 |
| Principal investigator 1 | Alkermes, Inc. | $739.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625852 |
| Principal investigator 1 | Alkermes, Inc. | $688.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625854 |
| Principal investigator 1 | Alkermes, Inc. | $6,136.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625856 |
| Principal investigator 1 | Alkermes, Inc. | $276.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208625868 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626018 |
| Principal investigator 1 | Alkermes, Inc. | $688.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626636 |
| Principal investigator 1 | Alkermes, Inc. | $1,892.00 | 01/17/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208626882 |
| Principal investigator 1 | iRhythm Technologies, Inc. | $40,000.00 | 01/15/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | STUDY-iSLEEP | No dispute reported | 06/30/2026 | 1244039842 |
| Principal investigator 1 | Noctrix Health, Inc. | $1,053.00 | 01/06/2025 | Non-covered Recipient Entity Bogan Sleep Consultants, LLC | THRIVE | No dispute reported | 06/30/2026 | 1254628911 |
| Principal investigator 1 | Alkermes, Inc. | $15,156.91 | 01/01/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 | No dispute reported | 06/30/2026 | 1208627060 |
| Principal investigator 1 | Alkermes, Inc. | $10,678.47 | 01/01/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 | No dispute reported | 06/30/2026 | 1208627134 |
| Principal investigator 1 | Alkermes, Inc. | $16,536.51 | 01/01/2025 | Non-covered Recipient Entity BOGAN SLEEP CONSULTANTS, LLC | An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia | No dispute reported | 06/30/2026 | 1208627210 |